CG Oncology (CGON)

• Market cap: $4.76B
• 1 day: 2.14%
• 5 days: 11.56%
• 1 month: 5.38%
• 3 months: 41.56%
• 6 months: 125.73%
• Year to date: 37.9%
• 1 year: 104.22%
• 5 years: 55.04%
• 10 years: 55.04%
• Sector: Healthcare
• Industry: Biotechnology

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113